Chemistry challenges in lead optimization: Silicon isosteres in drug discovery

Drug Discovery Today

Volumn 8, Issue 12, 2003, Pages 551-556

  Showell, Graham A ^a   Mills, John S ^a  

^a Amedis Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Bioisostere; Chemical Biology; Drug discovery; Drug Discovery; Intellectual property; Lead optimisation; Medicinal chemistry; Pharmaceutical Science; Sila substitution; Silicon

Indexed keywords

ALKANE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CARBON; FLUSILAZOLE; KARENITECIN; NEOSTIGMINE; ORGANOSILICON DERIVATIVE; PHYSOSTIGMINE; QUADROSILAN; SILICONE DERIVATIVE; SILPERISONE; TAC 101; TACRINE; UNCLASSIFIED DRUG; ZIFROSILONE;

CHEMICAL STRUCTURE; CLINICAL TRIAL; DECISION MAKING; DIARRHEA; DRUG DESIGN; DRUG INDUSTRY; ELECTRIC POTENTIAL; GASTROINTESTINAL SYMPTOM; HUMAN; LIPOPHILICITY; LUNG CANCER; MOLECULAR SIZE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PHYSICAL CHEMISTRY; PROSTATE CANCER; REVIEW; SIDE EFFECT; VERTIGO;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; ORGANOSILICON COMPOUNDS; PHARMACEUTICAL PREPARATIONS; SILICON;

EID: 0037785175     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02726-0     Document Type: Review

References (32)

1. Bernardelli P., et al. To market, to market - 2001. Annu. Rep. Med. Chem. 37:2002;257-277.
2. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 2:1997;436-444.
3. Mitchell T., Showell G.A. Design strategies for building drug-like chemical libraries. Curr. Opin. Drug Discov. Dev. 4:2001;314-318.
4. Steele P. Drug patenting in 2001. Expert Opin. Ther. Pat. 12:2002;3-10.
5. Ajay A., et al. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J. Med. Chem. 41:1998;3314-3324.
6. CMC is available from MDL Information Systems Inc, San Leandro, CA 94577, USA.
7. Bemis G.W., Murcko M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39:1996;2887-2893.
8. Bemis G.W., Murcko M.A. Properties of known drugs. 2. Sidechains. J. Med. Chem. 42:1999;5095-5099.
9. Patani G.A., LaVoie E.J. Bioisosterism: a rational approach in drug design. Chem. Rev. 96:1996;3147-3176.
10. Burger A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 37:1991;287-371.
11. Heinonen P., et al. Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2-silainden-2-yl)imidazole, a silicon analogue of atipamezole. Eur. J. Med. Chem. 31:1996;725-729.
12. 2A antagonists. Bioorg. Med. Chem. Lett. 4:1994;415-420.
13. Yoo B.R., et al. Synthesis and biological evaluation of [1-(1H-1,2-4-triazol-1-yl)alkyl]-1-silacyclopentanes. Pestic. Sci. 52:1998;138-144.
14. Tacke R., Wannagat U. Synthesis and properties of bioactive organo-silicon compounds. Top. Curr. Chem. 84:1979;1-75.
15. Tacke R., et al. Synthesis and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. J. Org. Chem. 640:2001;140-165.
16. Tacke, R. et al. (1987) Sila-procyclidine: a new synthesis as well as investigations of the peripheral and central cholinergic activity. Liebigs Ann. Chem., 51-57.
17. Tacke R., et al. Preparation and properties of the enantiomers of the antimuscarinic agents sila-procyclidine and sila-tricyclamol iodide: optically active silanols with silicon as the center of chirality. Chem. Ber. 120:1987;1229-1237.
18. Reichstat M.M., et al. Theoretical investigation of intermolecular hydrogen-bonded complexes in systems: substituted carbinols (silanols) - ketones or ethers. J. Mol. Struct. 244:1991;283-290.
19. Holtje H.D., Busch T. Theoretische untersuchungen an sila-analogen antichlinergika. Dtsch. Apoth. Ztg. 38:1986;2007-2011.
20. Woo D.V., et al. Pharmacological activity comparisons of barbiturates and their silicon analogues. Can. J. Pharm. Sci. 14:1979;12-14.
21. Chen C.-A., et al. Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem. Biol. 8:2001;1161-1166.
22. Mutahi M.W., et al. Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotension-converting enzyme. J. Am. Chem. Soc. 124:2002;7363-7375.
23. Garson L.R., Kirchner L.K. Organosilicon entities as prophylactic and therapeutic agents. J. Pharm. Sci. 60:1971;1113-1127.
24. Kocsis P., et al. Analysis of the mechanism of action of silperisone, a new centrally acting muscle relaxant candidate. Fundam. Clin. Pharmacol. 13:(suppl. 1):1999;S144.
25. Brufani M., et al. New acetylcholinesterase inhibitors. Drugs Future. 22:1997;397-410.
26. Cutler N.R., et al. Acetylcholinesterase inhibition by zifrosilone: Pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 58:1995;54-61.
27. Kurie J.M., et al. A dose-escalation, pharmacokinetic and safety study of oral TAC101 in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 19:2000;749.
28. Rizvi N.A., et al. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor alpha selective retinoid, in patients with advanced cancer. J. Clin. Oncol. 20:2002;3522-3532.
29. Palazzolo R.J., et al. Investigation of the toxicologic properties of a phenylmethylcyclosiloxane. Toxicol. Appl. Pharmacol. 21:1972;15-28.
30. Alfthan O., et al. Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study. Scand. J. Urol. Nephrol. 17:1983;37-43.
31. Collste L., et al. Clinical trial of a new antigonadotrophic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. Eur. Urol. 7:1981;85-88.
32. Schilsky R.L., et al. Phase I trial of karenitecin administered intravenously daily for five consecutive days in patients with advanced solid tumours using accelerated dose titration. Proc. Am. Soc. Clin. Oncol. 19:2000;758.